Repairing the eye - Nature Biotechnology

  • 📰 NatureBiotech
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 63%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Repairing the eye: Companies are pursuing interventions to edit, regenerate and reprogram eye tissue to restore lost vision

to hit its primary endpoint of corneal repair, it did have statistically significant effects on dryness, burning, stinging and photophobia . Because the vehicle used in the placebo group had antioxidant effects, it could have resulted in a higher than expected response in the control group, Chen said, as well as some effect on stinging. The company aims to move to a phase 3 trial early next year, administering lower volumes of vehicle.

The Wnt signal pathway is important during embryonic development for cellular migration and to determine a cell’s fate, and Endogena observed that its small molecule induced structural and functional improvements in mouse models of RP. Endogena’s co-founder and CEO Matthias Steger says: “We could see an improvement in vision even after three months.” If the program is successful, the company envisages intermittent dosing, to top up the photoreceptor population periodically.

“It’s conceivable that either by tinkering with the sequence of these transcription factors or finding the right combinations that we can get this reprogramming to occur”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 231. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

WSJ News Exclusive | CEO of Biotech Lobbying Group BIO on Leave Amid Clash Over DirectionDr. Michelle McMurry-Heath is on leave amid dissent within BIO, the biotechnology industry’s top lobbying group, about its direction and concern about its results, according to people familiar with the group.
Source: WSJ - 🏆 98. / 63 Read more »